Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models

CONTEXT: The advent of immune check inhibitors (ICIs) has tremendously changed the prognosis of metastatic renal cell carcinoma (mRCC), adding an unseen substantial overall survival benefit. These agents could be administered alone or in combination with anti–vascular endothelial growth factor (anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouzaid, Idir, Rioux-Leclercq, Nathalie, Khene, Zine-Eddine, Bensalah, Karim, Kammerer-Jacquet, Solène-Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review – Kidney Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789383/
https://www.ncbi.nlm.nih.gov/pubmed/36573246
http://dx.doi.org/10.1016/j.euros.2022.11.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789383/
https://www.ncbi.nlm.nih.gov/pubmed/36573246
http://dx.doi.org/10.1016/j.euros.2022.11.006

Ejemplares similares